Anxiety and Somatic Symptoms in Children and Adolescents Diagnosed with Attention-Deficit Hyperactivity Disorder

Background Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition typified by inattention, hyperactivity, and impulsivity. Comorbid psychiatric disorders are common among children and adolescents with ADHD. In this study, it was aimed to examine anxiety and somatic symptoms in children and adolescents with ADHD and the effect of methylphenidate treatment on these symptoms. Method Three groups were formed, consisting of 37 children and adolescents diagnosed with ADHD and received methylphenidate treatment, 37 newly diagnosed, treatment-naive children and adolescents with ADHD diagnosis, and 37 children and adolescents without the diagnosis of ADHD. The symptoms of ADHD in children were examined by using the DSM-IV-based child and adolescent behavior disorders screening and rating scale, the symptoms of anxiety were examined by using the screen for child anxiety-related disorders (SCARED), and somatic symptoms were examined by using the DSM-5 level 2 somatic symptom scale. Results In the newly diagnosed, treatment-naive with ADHD group, anxiety and somatic symptoms were found to be significantly higher compared to the ADHD group with methylphenidate treatment and the non-ADHD group. It was shown that the symptoms of panic disorder, generalized anxiety, and social phobia were observed more in the newly diagnosed, treatment-naive with ADHD group compared to the treatment group with ADHD. Conclusions It was determined that children and adolescents diagnosed with ADHD had more anxiety and somatic symptoms. Anxiety and somatic symptoms increased as the severity of ADHD symptoms increased. Anxiety and somatic symptoms were lower than in ADHD children receiving methylphenidate treatment. Clinicians should keep in mind to evaluate anxiety and somatic symptoms in children and adolescents with ADHD before the treatment.

[1]  K. Min,et al.  Effects of Methylphenidate on Somatic Symptoms and Brain Functional Connectivity in Adolescents with Attention Deficit Hyperactivity Disorder: A Pilot Study , 2022, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[2]  Xuerong Luo,et al.  Association Between Hyperactivity Symptoms and Somatic Complaints: Mediating and Moderating Mechanisms in Childhood Trauma and Life Events Among Chinese Male Adolescents , 2021, Frontiers in Psychiatry.

[3]  E. Harvey,et al.  Early Development of Comorbidity Between Symptoms of ADHD and Anxiety , 2021, Research on Child and Adolescent Psychopathology.

[4]  C. Lau,et al.  Diagnostic and Statistical Manual of Mental Disorders, 5th Ed.: DSM‐5 , 2020, The Wiley Encyclopedia of Personality and Individual Differences.

[5]  M. Timmerman,et al.  Stress Exposure and the Course of ADHD from Childhood to Young Adulthood: Comorbid Severe Emotion Dysregulation or Mood and Anxiety Problems , 2019, Journal of clinical medicine.

[6]  J. H. Andersen,et al.  Do negative childhood conditions increase the risk of somatic symptoms in adolescence? – a prospective cohort study , 2019, BMC Public Health.

[7]  P. Curatolo,et al.  Comorbidity between ADHD and anxiety disorders across the lifespan , 2019, International journal of psychiatry in clinical practice.

[8]  S. Gau,et al.  Comparative Efficacy of Methylphenidate and Atomoxetine on Emotional and Behavioral Problems in Youths with Attention-Deficit/Hyperactivity Disorder. , 2019, Journal of child and adolescent psychopharmacology.

[9]  F. Reimherr,et al.  ADHD and Anxiety: Clinical Significance and Treatment Implications , 2017, Current Psychiatry Reports.

[10]  Matthew D. Bramlett,et al.  Latent Class Analysis of ADHD Neurodevelopmental and Mental Health Comorbidities , 2017, Journal of developmental and behavioral pediatrics : JDBP.

[11]  P. Chokka,et al.  Adult ADHD and comorbid disorders: clinical implications of a dimensional approach , 2017, BMC Psychiatry.

[12]  M. Bonati,et al.  Comorbidity prevalence and treatment outcome in children and adolescents with ADHD , 2017, European Child & Adolescent Psychiatry.

[13]  T. Banaschewski,et al.  Attention-Deficit/Hyperactivity Disorder. , 2017, Deutsches Arzteblatt international.

[14]  Matthew A. Jarrett,et al.  Characteristics of Children With ADHD and Comorbid Anxiety , 2016, Journal of attention disorders.

[15]  I. Ondrejka,et al.  Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD , 2016, Pediatrics international : official journal of the Japan Pediatric Society.

[16]  M. Bloch,et al.  Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder. , 2015, Journal of child and adolescent psychopharmacology.

[17]  G. Salum,et al.  Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. , 2015, Journal of child psychology and psychiatry, and allied disciplines.

[18]  H. Steinhausen,et al.  Comorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study , 2015, ADHD Attention Deficit and Hyperactivity Disorders.

[19]  Abraham Weizman,et al.  The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety , 2014, International clinical psychopharmacology.

[20]  C. Ko,et al.  Association Between ADHD Symptoms and Anxiety Symptoms in Taiwanese Adolescents , 2014, Journal of attention disorders.

[21]  A. Bonillo,et al.  ADHD and functional somatic symptoms: structural equations of a conceptual model. , 2014, Child and adolescent mental health.

[22]  A. Karni,et al.  Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial , 2012, ADHD Attention Deficit and Hyperactivity Disorders.

[23]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[24]  A. Warnke,et al.  Developmental comorbidity in attention-deficit/hyperactivity disorder , 2010, Attention deficit and hyperactivity disorders.

[25]  J. Newcorn.  Managing ADHD and comorbidities in adults. , 2009, The Journal of clinical psychiatry.

[26]  E. Bixler,et al.  ADHD subtypes and comorbid anxiety, depression, and oppositional-defiant disorder: differences in sleep problems. , 2008, Journal of pediatric psychology.

[27]  M. Monuteaux,et al.  Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. , 2008, The American journal of psychiatry.

[28]  M. Stein,et al.  Nature of anxiety comorbid with attention deficit hyperactivity disorder in children from a pediatric primary care setting , 2008, Psychiatry Research.

[29]  B. Horta,et al.  The worldwide prevalence of ADHD: a systematic review and metaregression analysis. , 2007, The American journal of psychiatry.

[30]  A. Philalithis,et al.  Variations in prevalence of attention deficit hyperactivity disorder worldwide , 2006, European Journal of Pediatrics.

[31]  R. Ulloa,et al.  [Psychopathology associated to attention deficit hyperactivity disorder in school age children]. , 2006, Actas espanolas de psiquiatria.

[32]  P. Mattos,et al.  [Anxiety disorders in an attention-deficit/hyperactivity disorder clinical sample]. , 2005, Arquivos de neuro-psiquiatria.

[33]  P. Scheidt,et al.  Headache, stomachache, backache, and morning fatigue among adolescent girls in the United States: associations with behavioral, sociodemographic, and environmental factors. , 2004, Archives of pediatrics & adolescent medicine.

[34]  N. Erol,et al.  Symptoms Defined by Parents' and Teachers' Ratings in Attention-Deficit Hyperactivity Disorder: Changes with Age , 2004, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[35]  M. Rapport,et al.  Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. , 2002, Clinical psychology review.

[36]  John E. Cooper,et al.  Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR) , 2001, British Journal of Psychiatry.

[37]  C. Bell.  Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision: DSM-IV-TR Quick Reference to the Diagnostic Criteria from DSM-IV-TR , 2001 .

[38]  J. Oakman,et al.  Childhood attention deficit/hyperactivity disorder in adults with anxiety disorders , 1999, Psychological Medicine.

[39]  P. Ahmann,et al.  Placebo-controlled evaluation of Ritalin side effects. , 1993, Pediatrics.

[40]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[41]  R. Barkley,et al.  Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. , 1990, Pediatrics.

[42]  Ö. Aydemir,et al.  Validity and Reliability of the Turkish Version of DSM-5 Level 2 Somatic Symptom Scale (Child Form for 11-17 Years and Parent Form for 6-17 Years) , 2017 .